Vaccination is the main pharmaceutical intervention to reduce COVID-19 hospitalizations. I will present an assessment of the impact of SARS-CoV-2 vaccination strategies during the pandemic and in the post-pandemic period. The quick development and rollout of vaccines around the world opened possibilities for relaxing non-pharmaceutical interventions during the pandemic, but it was only with the large-scale rollout of vaccination that effective control of COVID-19 transmission was achieved. In the post-pandemic period, SARS-CoV-2 infection causes common cold- or flu-like illness in most individuals, but patients with chronic conditions still experience a higher chance of COVID-19 hospitalization. It is crucial to estimate COVID-19 burden in chronic patients and to determine how best to protect them from severe COVID-19. I will consider several age-structured models that have been fitted to age-specific data sources. The model population is stratified by age, risk due to chronic conditions, and immunity level. To stratify the population into risk groups due to pre-existing chronic conditions (low-, moderate-, and high-risk), I will compare the European classification by the European Centre for Disease Prevention and Control and the national classifications by the public health institutes in individual European countries. I will consider several strategies, namely vaccination of high-risk individuals, high- and moderate-risk individuals, individuals above 60 or 80 years old, and combinations of these strategies. I will discuss how best vaccination strategies differ depending on the metrics used for their evaluation: 1) maximum vaccination impact as quantified by the reduction in the number of hospitalizations due to vaccination; 2) maximum vaccination effectiveness as quantified by the number needed to vaccinate to prevent one hospitalization.